The pharmaceutical sector’s transformation has bought many opportunities for market disrupters. In this context, Alvogen has successfully established itself as a multibillion-dollar company

The US generic pharmaceuticals market is transforming thanks to the consolidation of smaller industry players, which has resulted in price erosion

A new ruling has scuppered plans for a $48bn merger between the second and third largest US health insurers as concerns over competition continue to grow

A new OECD report has criticised the pricing strategy of the pharmaceutical industry, claiming many new drugs are simply bad value for money

As the board of directors play tug of war with post-patent expiry strategies, responsibility for Teva’s future has fallen to ‘turnaround specialist’ Erez Vigodman

The Japanese Health Ministry has filed a criminal complaint against the world’s second biggest pharmaceutical company Novartis following exaggerated advertising claims